Last reviewed · How we verify
Povidone Iodine Topical
Povidone iodine is a broad-spectrum antimicrobial agent that releases iodine to disrupt microbial cell membranes and proteins, killing bacteria, viruses, fungi, and protozoa on contact.
Povidone iodine is a broad-spectrum antimicrobial agent that releases iodine to disrupt microbial cell membranes and proteins, killing bacteria, viruses, fungi, and protozoa on contact. Used for Antisepsis and disinfection of skin wounds and surgical sites, Minor cuts, scrapes, and abrasions, Preoperative skin preparation.
At a glance
| Generic name | Povidone Iodine Topical |
|---|---|
| Also known as | Iodophor, Betadine, Profend Nasal Decolonization Kit (SKU # X12048) |
| Sponsor | Mary K Hayden |
| Drug class | Topical antiseptic/disinfectant |
| Target | Microbial cell membranes and proteins (non-selective) |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Infection Prevention |
| Phase | FDA-approved |
Mechanism of action
The iodine component penetrates microbial cell walls and oxidizes essential proteins and nucleic acids, leading to rapid cell death. Povidone serves as a carrier that stabilizes the iodine and allows sustained release at the application site. This makes it effective for topical antisepsis and disinfection of skin and wounds.
Approved indications
- Antisepsis and disinfection of skin wounds and surgical sites
- Minor cuts, scrapes, and abrasions
- Preoperative skin preparation
Common side effects
- Skin irritation or burning at application site
- Allergic contact dermatitis
- Iodine sensitivity reactions
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Optimizing the Timing for Facial Surgical Dressing Removal (NA)
- PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study) (PHASE4)
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
- Pilot Evaluation of the Application Procedure on the Antimicrobial Effects of 2 Antiseptics (PHASE3)
- Nasal Antisepsis for C. Auris Prevention (PHASE4)
- The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine (PHASE4)
- PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Povidone Iodine Topical CI brief — competitive landscape report
- Povidone Iodine Topical updates RSS · CI watch RSS
- Mary K Hayden portfolio CI